ImmunoPET predicts response to met-targeted radioligand therapy in models of pancreatic cancer resistant to Met kinase inhibitors Journal Article


Authors: Escorcia, F. E.; Houghton, J. L.; Abdel-Atti, D.; Pereira, P. R.; Cho, A.; Gutsche, N. T.; Baidoo, K. E.; Lewis, J. S.
Article Title: ImmunoPET predicts response to met-targeted radioligand therapy in models of pancreatic cancer resistant to Met kinase inhibitors
Abstract: Background: Pancreatic ductal adenocarcinoma (PDAC) has limited standard of care therapeutic options. While initially received with enthusiasm, results from targeted therapy with small molecule tyrosine kinases inhibitors (TKIs) have been mixed, in part due to poor patient selection and compensatory changes in signaling networks upon blockade of one or more kinase of tumors. Here, we demonstrate that in PDACs otherwise resistant to rational kinase inhibition, Met-directed immuno-positron emission tomography (immunoPET) can identify targets for cell-signaling independent targeted radioligand therapy (RLT). In this study, we use Met-directed immunoPET and RLT in models of human pancreatic cancer that are resistant to Met- and MEK-selective TKIs, despite over-expression of Met and KRAS-pathway activation. Methods: We assessed cell membrane Met levels in human patient samples and pancreatic ductal adenocarcinoma (PDAC) cell lines (BxPC3, Capan2, Suit2, and MIA PaCa-2) using immunofluorescence, flow cytometry and cell-surface biotinylation assays. To determine whether Met expression levels correlate with sensitivity to Met inhibition by tyrosine kinase inhibitors (TKIs), we performed cell viability studies. A Met-directed imaging agent was engineered by labeling Met-specific onartuzumab with zirconium-89 (Zr-89) and its in vivo performance was evaluated in subcutaneous and orthotopic PDAC xenograft models. To assess whether the immunoPET agent would predict for targeted RLT response, onartuzumab was then labeled with lutetium (Lu-177) as the therapeutic radionuclide to generate our [177Lu]Lu-DTPA-onartuzumab RLT agent. [177Lu]Lu-DTPA-onartuzumab was administered at 9.25MBq (250μCi)/20μg in three fractions separated by three days in mice subcutaneously engrafted with BxPC3 (high cell-membrane Met) or MIA PaCa-2 (low cell-membrane Met). Primary endpoints were tumor response and overall survival. Results: Flow cytometry and cell-surface biotinylation studies showed that cell-membrane Met was significantly more abundant in BxPC3, Capan2, and Suit2 when compared with MIA PaCa-2 pancreatic tumor cells. Crizotinib and cabozantinib, TKIs with known activity against Met and other kinases, decreased PDAC cell line viability in vitro. The TKI with the lowest IC50 for Met, capmatinib, had no activity in PDAC lines. No additive effect was detected on cell viability when Met-inhibition was combined with MEK1/2 inhibition. We observed selective tumor uptake of [89Zr]Zr-DFO-onartuzumab in mice subcutaneously and orthotopically engrafted with PDAC lines containing high cell-surface levels of Met (BxPC3, Capan2, Suit2), but not in mice engrafted with low cell-surface levels of Met (MIA PaCa-2). Significant tumor growth delay and overall survival benefit were observed in both BxPC3 and MIA PaCa-2 engrafted animals treated with RLT when compared to controls, however, the benefit was more pronounced and more durable in the BxPC3 engrafted animals treated with [177Lu]Lu-DTPA-onartuzumab RLT. Conclusions: Our findings demonstrate that while over-expression of Met is not predictive of Met-directed TKI response, immunoPET can detect Met over-expression in vivo and predicts for therapeutic response to Met-selective RLT. This phenomenon can be exploited for other Met-overexpressing tumor types specifically, and to any differentially overexpressed surface molecule more broadly. © The author(s).
Keywords: controlled study; human tissue; protein expression; unclassified drug; overall survival; nonhuman; pancreas cancer; positron emission tomography; mouse; animal tissue; cell viability; animal experiment; animal model; in vivo study; antineoplastic activity; in vitro study; tumor xenograft; drug resistance; molecular imaging; prediction; protein tyrosine kinase inhibitor; drug uptake; drug response; pancreas adenocarcinoma; pancreatic cancer; radioimmunotherapy; drug sensitivity; scatter factor receptor; immunopet; radioligand; crizotinib; trametinib; cabozantinib; human; article; onartuzumab; ic50; capmatinib; positron emission tomography-computed tomography; mia paca-2 cell line; capan-2 cell line; dfo onartuzumab zr 89; pentetic acid onartuzumab lu 177; bxpc-3 cell line; immuno positron emission tomography; suit-2 cell line
Journal Title: Theranostics
Volume: 10
Issue: 1
ISSN: 1838-7640
Publisher: Ivyspring International Publisher  
Date Published: 2020-01-01
Start Page: 151
End Page: 165
Language: English
DOI: 10.7150/thno.37098
PUBMED: 31903112
PROVIDER: scopus
PMCID: PMC6929627
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Jason S Lewis
    356 Lewis
  2. Andrew Cho
    5 Cho